Across TCGA pan-cancer cohorts, KCNK17 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KCNK17 data layer compared with 27 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher KCNK17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KCNK17 expression acts as an unfavorable survival marker.
GBM and LSCC are the cancer types where KCNK17 mass-spec protein most reproducibly stratifies survival.